{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-017915","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.740228+00:00","generated_at":"2026-05-26T23:19:51.108066+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M","bullets":["Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).","clonoSEQ test volume Q4 20,945 tests (+34% YoY); full year 76,105 tests (+35%).","Net loss Q4 $33.7M vs $69.5M a year ago; FY net loss $159.6M vs $225.3M. Adjusted EBITDA loss Q4 $16.4M vs $24.7M.","FY2025 guidance: MRD revenue $175-185M; total operating expenses $340-350M; cash burn $60-70M.","FDA ODAC unanimously voted to support MRD as primary endpoint for accelerated approval in multiple myeloma."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-017915","json":"https://secwatch.observer/filing/0000950170-25-017915.json","markdown":"https://secwatch.observer/filing/0000950170-25-017915.md","text":"https://secwatch.observer/filing/0000950170-25-017915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017025017915/0000950170-25-017915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017025017915/adpt-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:19:51.108066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}